Corixa on Bexxar
"Answers to many questions" raised by FDA in March 16 "complete review" letter for non-Hodgkin's therapy Bexxar "are now complete and we are focused on finishing final study reports for two of the three additional studies that we previously announced would be submitted to the agency," Corixa says June 20. "We are waiting the results of independent radiology and oncology reviews of response and duration of response data...We will file our response with the agency when the independent review data is final"
You may also be interested in...
GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011